This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458509102920v1 15/6/721    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bernal, F Articles by Kieseier, B. Search for Related Content PubMed PubMed Citation Articles by Bernal, F Articles by Kieseier, B. Social Bookmarking                         What's this?

Regulation of matrix metalloproteinases and their inhibitors by interferon-: a longitudinal study in multiple sclerosis patients

Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany

^* To whom correspondence should be addressed.

	Abstract

Background

Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)- is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN- on the other 20 members of the MMP family.

Methods

This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN- therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR.

Results

RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time.

Conclusions

These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN- in MS for at least 6 months.

Key Words: disease modifying therapies, immunology, interferon-, metalloproteinases, multiple sclerosis, tissue inhibitors of metalloproteinases, treatment

First published on April 21, 2009, doi:10.1177/1352458509102920

Multiple Sclerosis 2009;15:721.

A more recent version of this article appeared on June 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?